阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALNY 阿尔尼拉姆制药公司

休市中 04-26 16:00:00 EDT

143.31

-0.40

-0.28%

盘后143.31

+0.000.00%

19:42 EDT

最高146.07	最低143.00	成交量47.91万
今开144.08	昨收143.71	日振幅2.13%
总市值181.22亿	流通市值180.45亿	总股本1.26亿
成交额6,919万	换手率0.38%	流通股本1.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"阿尔尼拉姆制药公司","latestPrice":143.31,"timestamp":1714161600000,"preClose":143.71,"halted":0,"volume":479139,"hourTrading":{"tag":"盘后","latestPrice":143.31,"preClose":143.31,"latestTime":"19:42 EDT","volume":7356,"amount":1054200.2,"timestamp":1714174953456},"delay":0,"floatShares":125914234,"shares":126452099,"eps":-3.524586,"marketStatus":"休市中","marketStatusCode":7,"change":-0.4,"latestTime":"04-26 16:00:00 EDT","open":144.08,"high":146.065,"low":143,"amount":69185553.80562,"amplitude":0.021328,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.524586,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714377600000},"adr":0,"listingDate":1085630400000,"adjPreClose":143.71,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":143.71,"preClose":143.71,"latestTime":"08:55 EDT","volume":15,"amount":2155.65,"timestamp":1714136105980},"postHourTrading":{"tag":"盘后","latestPrice":143.31,"preClose":143.31,"latestTime":"19:42 EDT","volume":7356,"amount":1054200.2,"timestamp":1714174953456},"volumeRatio":0.946315877663085},"requestUrl":"/m/hq/s/ALNY/tweets","defaultTab":"tweets","newsList":[{"id":"2417415513","title":"罗氏和 Alnylam 称降压药在中期试验中获得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2417415513","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417415513?lang=zh_cn&edition=full","pubTime":"2024-03-05 21:27","pubTimestamp":1709645234,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社法兰克福3月5日 - 罗氏公司  和合作伙伴Alnylam公司  周二称，在一项二期试验中，他们研制的治疗高血压的试验性药物在与标准疗法联合使用时显示出了效果。罗氏公司周二在一份声明中说，KARDIA-2二期试验将于4月6日在亚特兰大举行的美国心脏病学会科学年会上公布全部结果。去年 7 月，罗氏同意开发 Alnylam 的 zilebesiran 并将其商业化，用于治疗高血压这一全球心血管疾病的主要病因。罗氏当时向 Alnylam 支付了 3.1 亿美元的预付款，并支付了里程碑付款，使这笔交易的潜在价值高达 28 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413782240","title":"阿里拉姆制药盘中异动 下午盘急速拉升5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413782240","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413782240?lang=zh_cn&edition=full","pubTime":"2024-02-23 03:00","pubTimestamp":1708628433,"startTime":"0","endTime":"0","summary":"北京时间2024年02月23日03时00分，阿里拉姆制药股票出现波动，股价大幅上涨5.05%。截至发稿，该股报162.55美元/股，成交量61.5857万股，换手率0.49%，振幅5.29%。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为2.26%。阿里拉姆制药公司简介：Alnylam Pharmaceuticals是RNA干扰治疗研究的领导者。RNAi是细胞内一种自然发生的生物通路，用于序列特异性沉默和调控基因表达。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022303003387e724fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022303003387e724fe&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2412997488","title":"阿里拉姆制药2023财年实现净利润-4.40亿美元，同比增加61.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2412997488","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2412997488?lang=zh_cn&edition=full","pubTime":"2024-02-19 00:20","pubTimestamp":1708273216,"startTime":"0","endTime":"0","summary":"12月31日，阿里拉姆制药公布财报，公告显示公司2023财年净利润为-4.40亿美元，同比增加61.10%；其中营业收入为18.28亿美元，同比增加76.28%，每股基本收益为-3.52美元。从资产负债表来看，阿里拉姆制药总负债40.51亿美元，其中短期债务96.50百万美元，资产负债比为0.95，流动比率为3.09。机构评级：截至2023年12月31日，当前有23家机构对阿里拉姆制药目标价做出预测，其中目标均价为219.35美元，其中最低目标价为136.00美元，最高目标价为395.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240219002028879e45cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240219002028879e45cd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411686106","title":"美国研究综述-阿尔伯马尔、Dropbox、英伟达","url":"https://stock-news.laohu8.com/highlight/detail?id=2411686106","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411686106?lang=zh_cn&edition=full","pubTime":"2024-02-16 21:53","pubTimestamp":1708091615,"startTime":"0","endTime":"0","summary":"    路透社2月16日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，包括 Albemarle、Dropbox 和 Nvidia。要闻 * Albemarle Corp   ：摩根大通将目标价从130美元下调至115美元  * Bloom Energy Corp   ：KeyBanc将其评级从 \"增持 \"下调至 \"行业权重\"。* Dropbox Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。* Nvidia Corp   ：奥本海默将目标价从650美元上调至850美元  * Tyler Technologies Inc   ：Piper Sandler将目标价从480美元上调至520美元  以下是路透社周五报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411251632","title":"美国研究综述-英伟达、Albemarle、Dropbox","url":"https://stock-news.laohu8.com/highlight/detail?id=2411251632","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411251632?lang=zh_cn&edition=full","pubTime":"2024-02-16 17:25","pubTimestamp":1708075529,"startTime":"0","endTime":"0","summary":"    路透社2月16日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，包括 Albemarle、Dropbox 和 Nvidia。要闻  * Albemarle Corp   ：摩根大通将目标价从130美元下调至115美元  * Deere & Co   ：大和资本市场将目标价从425美元下调至400美元  * Dropbox Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411635884","title":"美国研究综述-阿尔伯马尔、Dropbox、泰勒科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2411635884","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411635884?lang=zh_cn&edition=full","pubTime":"2024-02-16 15:19","pubTimestamp":1708067998,"startTime":"0","endTime":"0","summary":"    路透社2月16日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，包括 Albemarle、Dropbox 和 Tyler Technologies。要闻  * Albemarle Corp   ：摩根大通将目标价从130美元下调至115美元  * Deere & Co   ：大和资本市场将目标价从425美元下调至400美元  * Dropbox Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。* Nvidia Corp   ：奥本海默将目标价从650美元上调至850美元              * Tyler Technologies Inc   ：Piper Sandler将目标价从480美元上调至520美元  以下是路透社周五报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411252722","title":"BUZZ-竞争对手 Alnylam 更改心脏病药物研究目标后，BridgeBio 公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2411252722","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411252722?lang=zh_cn&edition=full","pubTime":"2024-02-16 03:34","pubTimestamp":1708025681,"startTime":"0","endTime":"0","summary":"    2月15日 - ** 制药商Bridgebio Pharma   股价上涨19.4%，至41.01美元 ** 如果涨势得以保持，股价将创7个多月来最大单日涨幅 ** Alnylam   修改了  关键目标，以测试其药物Amvuttra作为ATTR淀粉样变性相关心肌病的治疗方法。** BBIO正在开发一种名为acoramidis的药物，用于治疗同一种疾病，目前正处于后期试验阶段。** 瑞穗证券公司表示：\"除非公司觉得有必要，否则不会随便改变统计计划。** 股价在过去 12 个月中增长了两倍多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411400535","title":"Alnylam Pharmaceuticals Inc 报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2411400535","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411400535?lang=zh_cn&edition=full","pubTime":"2024-02-16 00:15","pubTimestamp":1708013754,"startTime":"0","endTime":"0","summary":"   * Alnylam Pharmaceuticals Inc    公布的截至 12 月的季度调整后每股亏损 1.10 美元，高于去年同期的每股收益 1.68 美元。25 位分析师对该季度的平均预期是每股亏损 1.32 美元。华尔街预期为每股亏损 3.08 美元至-1 美分。* 营收同比增长 31.2%，达到 4.3972 亿美元；分析师预期为 4.429 亿美元。* Alnylam Pharmaceuticals Inc公布的本季度每股收益为亏损1.10美元。* 该公司一季度亏损 1.3787 亿美元。* Alnylam Pharmaceuticals Inc 本季度股价下跌了 14.2%。华尔街对 Alnylam Pharmaceuticals Inc 的 12 个月目标价中位数为 232.00 美元。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411544882","title":"阿里拉姆制药盘中异动 股价大跌8.54%报150.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2411544882","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411544882?lang=zh_cn&edition=full","pubTime":"2024-02-15 22:32","pubTimestamp":1708007539,"startTime":"0","endTime":"0","summary":"北京时间2024年02月15日22时32分，阿里拉姆制药股票出现异动，股价急速下跌8.54%。截至发稿，该股报150.13美元/股，成交量43.619万股，换手率0.35%，振幅2.11%。最近的财报数据显示，该股实现营业收入7.51亿美元，净利润1.48亿美元，每股收益1.18美元，毛利6.66亿美元，市盈率-36.53倍。阿里拉姆制药股票所在的生物技术行业中，整体跌幅为0.06%。阿里拉姆制药公司简介：Alnylam Pharmaceuticals是RNA干扰治疗研究的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240215223220818f71f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240215223220818f71f4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411545727","title":"BUZZ-Alnylam 因修改心脏病治疗研究目标而失败","url":"https://stock-news.laohu8.com/highlight/detail?id=2411545727","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411545727?lang=zh_cn&edition=full","pubTime":"2024-02-15 22:07","pubTimestamp":1708006059,"startTime":"0","endTime":"0","summary":"    2月15日 - ** Alnylam Pharmaceuticals  股价盘前下跌~9%，至149.73美元 ** 该公司称已修改了一项备受期待的后期研究的主要和次要目标，该研究将测试其治疗一种心脏病的实验性药物 ** 候选药物vutrisiran是一种皮下注射药物，目前正处于治疗ATTR淀粉样变性相关心肌病的后期试验阶段。** ATTR淀粉样变性的特征是转甲状腺素蛋白在器官和组织中的异常沉积。** vutrisiran在美国被批准用于治疗遗传性ATTR淀粉样变性成人患者的神经损伤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411913133","title":"阿里拉姆制药盘中异动 下午盘大幅跳水5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2411913133","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411913133?lang=zh_cn&edition=full","pubTime":"2024-02-14 04:09","pubTimestamp":1707854975,"startTime":"0","endTime":"0","summary":"北京时间2024年02月14日04时09分，阿里拉姆制药股票出现波动，股价大幅跳水5.00%。截至发稿，该股报160.88美元/股，成交量40.1906万股，换手率0.32%，振幅3.31%。阿里拉姆制药股票所在的生物技术行业中，整体跌幅为1.33%。阿里拉姆制药公司简介：Alnylam Pharmaceuticals是RNA干扰治疗研究的领导者。RNAi是细胞内一种自然发生的生物通路，用于序列特异性沉默和调控基因表达。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402140409367a43814e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402140409367a43814e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411527813","title":"Alnylam Pharmaceuticals Inc    预计每股亏损 1.32 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2411527813","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411527813?lang=zh_cn&edition=full","pubTime":"2024-02-13 22:04","pubTimestamp":1707833049,"startTime":"0","endTime":"0","summary":"   * Alnylam Pharmaceuticals Inc     将于2月15日公布截至2023年12月31日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，21位分析师的平均预期显示，这家总部位于马萨诸塞州剑桥市的公司的营收预计将从去年同期的3.3504亿美元增长32.2%，达到4.4289亿美元。   * LSEG 分析师对 Alnylam Pharmaceuticals Inc 的平均预期是每股亏损 1.32 美元。* 华尔街对 Alnylam Pharmaceuticals Inc 的 12 个月目标价中值为 232.00 美元，高于其上次收盘价 169.34 美元。2月13日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2404360394","title":"美国研究综述-伯灵顿商店、Carrols 餐厅、Mastec","url":"https://stock-news.laohu8.com/highlight/detail?id=2404360394","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2404360394?lang=zh_cn&edition=full","pubTime":"2024-01-18 02:52","pubTimestamp":1705517520,"startTime":"0","endTime":"0","summary":"    路透1月17日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括伯灵顿百货公司、Carrols Restaurant Group 和 Mastec。要点 * Ambrx Biopharma Cayman Inc   ：贝雅将其评级下调至中性 * Burlington Stores Inc   ：Piper Sandler将其评级从中性上调至增持  * Carrols Restaurant Group Inc   ：Stephens将其评级从 \"增持 \"下调至 \"等权重\"。* Mastec Inc   ：贝尔德将其评级从 \"跑赢大盘 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2401586229","title":"美国研究综述-Agilon Health、戴尔科技、Fabrinet","url":"https://stock-news.laohu8.com/highlight/detail?id=2401586229","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2401586229?lang=zh_cn&edition=full","pubTime":"2024-01-08 20:50","pubTimestamp":1704718259,"startTime":"0","endTime":"0","summary":"    路透1月8日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 Agilon Health、戴尔科技和 Fabrinet。要闻  * Agilon Health Inc   ：加拿大皇家银行将目标价从23美元下调至11美元 * Brown & Brown Inc   ：加拿大皇家银行将其评级从 \"行业表现 \"上调至 \"跑赢大盘\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2393735416","title":"阿里拉姆制药盘中异动 股价大涨5.08%报190.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2393735416","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2393735416?lang=zh_cn&edition=full","pubTime":"2023-12-23 00:32","pubTimestamp":1703262760,"startTime":"0","endTime":"0","summary":"北京时间2023年12月23日00时32分，阿里拉姆制药股票出现异动，股价大幅上涨5.08%。截至发稿，该股报190.34美元/股，成交量16.3242万股，换手率0.13%，振幅4.64%。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为1.60%。阿里拉姆制药公司简介：Alnylam Pharmaceuticals是RNA干扰治疗研究的领导者。RNAi是细胞内一种自然发生的生物通路，用于序列特异性沉默和调控基因表达。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231223003240790318fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231223003240790318fe&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2380966949","title":"阿里拉姆制药盘中异动 股价大跌5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2380966949","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2380966949?lang=zh_cn&edition=full","pubTime":"2023-11-02 22:10","pubTimestamp":1698934224,"startTime":"0","endTime":"0","summary":"北京时间2023年11月02日22时10分，阿里拉姆制药股票出现波动，股价急速下跌5.27%。截至发稿，该股报148.73美元/股，成交量6.1768万股，换手率0.05%，振幅8.50%。机构评级方面，在所有29家参与评级的机构中，72%的券商给予买入建议，28%的券商给予持有建议，无券商给予卖出建议。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为1.59%。阿里拉姆制药公司简介：Alnylam Pharmaceuticals是RNA干扰治疗研究的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023110222102483995ce7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023110222102483995ce7&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":-0.0076},{"period":"1month","weight":-0.0718},{"period":"3month","weight":-0.2021},{"period":"6month","weight":-0.0557},{"period":"1year","weight":-0.269},{"period":"ytd","weight":-0.2513}],"compareEarnings":[{"period":"1week","weight":0.0265},{"period":"1month","weight":-0.0285},{"period":"3month","weight":0.0428},{"period":"6month","weight":0.2376},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0693}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alnylam Pharmaceuticals, Inc.是一家特拉华州公司，成立于2003年5月。该公司是一家研发基于RNA或RNAi干涉为新型治疗手段的生物制药公司。RNAi是一种在生物体内细胞中自然产生的选择性沉默及调控表达的特定基因。由于许多疾病是因为特定基因的不适当活动引起的，通过RNAi对于基因的选择性沉默能力可以为治疗许多人类疾病提供一种新的途径。公司认为，通过RNAi原理工作的药物有潜力成为的一种新的药物分类，诸如小分子药物、蛋白质药物以及抗体药物等。通过已经建立RNAi的知识产权以及专业技术，公司正在开发一套生物化学方法以帮助公司建立一个系统，通过该系统可以研发改进RNAi对于各种疾病的治疗方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.031314},{"month":2,"riseRate":0.5,"avgChangeRate":0.008316},{"month":3,"riseRate":0.45,"avgChangeRate":-0.018527},{"month":4,"riseRate":0.4,"avgChangeRate":-0.019646},{"month":5,"riseRate":0.578947,"avgChangeRate":0.035681},{"month":6,"riseRate":0.6,"avgChangeRate":0.035552},{"month":7,"riseRate":0.7,"avgChangeRate":0.108614},{"month":8,"riseRate":0.55,"avgChangeRate":0.028475},{"month":9,"riseRate":0.5,"avgChangeRate":0.034438},{"month":10,"riseRate":0.4,"avgChangeRate":-0.044685},{"month":11,"riseRate":0.8,"avgChangeRate":0.089497},{"month":12,"riseRate":0.5,"avgChangeRate":0.016329}],"exchange":"NASDAQ","name":"阿尔尼拉姆制药公司","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿尔尼拉姆制药公司,ALNY,阿尔尼拉姆制药公司股票,阿尔尼拉姆制药公司股票老虎,阿尔尼拉姆制药公司股票老虎国际,阿尔尼拉姆制药公司行情,阿尔尼拉姆制药公司股票行情,阿尔尼拉姆制药公司股价,阿尔尼拉姆制药公司股市,阿尔尼拉姆制药公司股票价格,阿尔尼拉姆制药公司股票交易,阿尔尼拉姆制药公司股票购买,阿尔尼拉姆制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}